Cristina Csimma

Cristina Csimma is the founder of Cydan II, Inc. Current jobs include Chairman at Caraway Therapeutics, Inc. since 2019, Executive Chairman at Sardona Therapeutics, Inc., Independent Director at Asgard Therapeutics AB, and Member-Managers Board at New York Blood Center, Inc. Former jobs include President & Chief Executive Officer at Cydan LLC, Chairman at Forendo Pharma Oy from 2020 to 2021, Executive Chairman at Exonics Therapeutics, Inc. from 2016 to 2017, Independent Director at Catalent JNP, Inc. from 2010 to 2018, Associate Director-Clinical Research at Genetics Institute LLC from 1988 to 2000, Independent Director at Idera Pharmaceuticals, Inc., Independent Director at Seneca Biopharma, Inc., Director-Clinical Research & Development at Wyeth-Ayerst Research in 2001, Senior Director-Translational Research at Pfizer Pharmaceuticals, Inc. in 2006, Director at T1D Exchange from 2018 to 2020, Independent Non-Executive Director at Syncona Ltd., Independent Director at Vtesse, Inc. from 2014 to 2017, Independent Director at Palisade Bio, Inc. from 2017 to 2024, Independent Director at Aceragen, Inc. from 2019 to 2023, Vice President-Drug Development at Virdante Pharmaceuticals, Inc. from 2009 to 2011, Principal at Dana-Farber Cancer Institute, Inc. from 1983 to 1988, and Principal at Clarus Ventures LLC.
Education includes undergraduate and doctorate degrees from Massachusetts College of Pharmacy & Health Science and a graduate degree from Northeastern University.